Effect of cisplatin on cell death and DNA crosslinking in rat mammary adenocarcinoma in vitro

Acta Medica Okayama

Volumn 53, Issue 5, 1999, Pages 201-208

  Yamamoto, Junko ^a   Miyagi, Yasunari ^a   Kawanishi, Kunihiro ^a   Yamada, Shinako ^a   Miyagi, Yuji ^a   Kodama, Junichi ^a   Yoshinouchi, Mitsuo ^a   Kudo, Takafumi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cisplatin; Crosslink; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CROSS LINKING REAGENT; DNA;

ADENOCARCINOMA; ANIMAL; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; KINETICS; METABOLISM; PATHOLOGY; RAT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL SURVIVAL; CISPLATIN; CROSS-LINKING REAGENTS; DNA; FEMALE; KINETICS; MAMMARY NEOPLASMS, ANIMAL; RATS; TUMOR CELLS, CULTURED;

EID: 0033210050     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T and Inaba M: Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol (1988) 21, 185-190.
2. Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA and Pinedo HM: Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther (1986) 39, 136-144.
3. Ma J, Verweij J, Kolker HJ, van Ingen HE, Stoter G and Schellens JH: Pharmacokinetic-dynamic relationship of cisplatin in vitro: Simulation of an i.v. bolus and 3 h and 20h infusion. Br J Cancer (1994) 69, 858 -862.
4. Miyagi Y, Zhang H and Wheeler K: Radiation-induced DNA damage in tumors and normal tissues: IV. Influence of proliferation status and cell type on the formation of oxygen-dependent DNA damage in cultured cells. Radiat Res (1997) 148, 29-34.
5. Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, O'Leary GP Jr, Griffin H, Phaneuf MA, O'Rourke A and Calabresi P: Cisplatin administration as a countinuous 5-day infusion: Plasma platinum levels and urine platinum excretion. Cancer Treat Rep (1986) 70, 1215-1217.
6. Zwelling LA, Anderson T and Kohn KW: DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxocity. Cancer Res (1979) 39, 365-369.
7. Plooy AC, van Dijk M and Lohman PH: Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxocity, mutagenicity, and antitumor activity. Cancer Res (1984) 44, 2043-2051.
8. Strandberg MC, Bresnick E and Eastman A: The significance of DNA crosslinking to cis-diamminedichloroplatinum(II)-induced cytotoxocity in sensitive and resistant lines of murine leukemia L1210 cells. Chem-Biol Interactions (1982) 39, 169-180.
9. Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG and Kampinga HH: Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer (1997) 75, 1735-1743.
10. Cryer JE, Johnson SW, Engelsberg BN and Billings PC: Analysis of HMG protein binding to DNA modified with the anticancer cisplatin. Cancer Chemother Pharmacol (1996) 38, 163-168.
11. Kohn KW and Cheng YC: Development of Target-Oriented Anticancer Drugs. Raven Press, New York (1983) pp 181-188.
12. Plooy AC, van Dijk M, Berends F and Lohman PH: Formation and repair of DNA interstrand cross-links in relation to cytotoxocity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res (1985) 45, 4178-4184.
13. Roberts JJ, Knox RJ, Pera MF, Friedlos F and Lydall PA: Platinum and other metal coordination compounds; in Cancer Chemotherapy, Nicolini M ed, Nijhoff, Boston (1988) pp 16-31.
14. Roberts JJ, Chagas C and Pullman B: Molecular Mechanisms of Carcinogenic and Antitumor Activity. Pontifica Academia Scientarium, Vatican City (1987) pp 463-489.
15. Tomasz M, Lipman R, Crowdary D, Pawlak J, Verdine GL and Nakanishi K: Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science (1987) 235, 1204-1208.
16. Zou Y, Van Houten B and Farrell N: Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and dinuclear platinum complexes. Biochemistry (1994) 33, 5404-5410.
17. Lemaire MA, Schwartz A, Rahmouni AR and Leng M: Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA (1991) 88,1982-1982.
18. Lawley PD and Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res (1996) 355, 13-40.
19. Roberts JJ and Friedlos F: The frequency of interstrand cross-links in DNA following reaction of cis-dimminedichloroplatinum(II) with cells in culture or DNA in vitro: Stability of DNA cross-links and their repair. Chem Biol Interact (1982) 39, 181-189.
20. Huang H, Zhu L, Reid BR, Drobny GP and Hopkins PB: Solution structure of a cisplatin-induced DNA interstrand cross-link. Science (1995) 270, 1842-1845.
21. Roberts JJ, Friedlos F, Scott D, Ormerod MG and Rawlings CJ: The unique sensitivity of Walker rat tumour cells to difunctional agents is associated with a failure to recover from inhibition of DNA systhesis and increased chromosome damage. Mutat Res (1986) 166, 169-181.
22. Hospers GA, Meiler C, de Leij L, Uges DR, Mulder NH and de Vries EG: A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance, Int J Cancer (1990) 46, 138-144.
23. Pérez C, Leng M and Malinge JM: Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res (1997) 25, 896-903.
24. Kaneta T, Takai Y, Nemoto K, Kakuto Y, Ogawa Y, Ariga H, Maruoka S, Ishibashi T, Hosoi Y and Yamada S: Effects of combination chemoradiotherapy with daily low-dose CDDP for esophageal cancer - results of a randomized trial. Jpn J Cancer Chemother (1997) 24, 2099-2104 (in Japanese).
25. Saito Y, Mori K, Yokoi K, Tominaga K and Miyazawa N: Pilot phase II study of 5-day continuous infusion of cisplatin in treatment of non-small cell lung cancer. Jpn J Cancer Chemother (1989) 16, 2081 -2086 (in Japanese).
26. Terashima M, Ikeda K, Takagane A, Sasaki N, Abe K, Nishizuka S, Yonezawa H, Irinoda T, Nakaya T, Oyama K and Saito K: Pharmacokinetic analysis of low-dose intra-peritoneal cis-platinum administration. Jap J Cancer Chemother (1998) 25, 1433-1435 (in Japanese).
27. Yagihashi A, Sasaki K, Hirata K and Yamamitsu S: Study of serum CDDP concentrations in patients with advanced or recurrent adeno- or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV). Jpn J Cancer Chemother (1996) 23, 63 -67 (in Japanese).